Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 5, 2008, Pages 533.e1-533.e8

  Ødegaard, Elin ^a   Davidson, Ben ^b,c   Engh, Vibeke ^a   Onsrud, Mathias ^a,b   Staff, Anne Cathrine ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

biomarker; borderline tumors of the ovary; calprotectin; endoglin; ovarian carcinoma

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; ENDOGLIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EFFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 54849409198     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.04.004     Document Type: Article

References (26)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Ozols R.F., Rubin S.C., Thomas G., and Robboy S. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., and Young R.C. (Eds). Principles and practice of gynecologic oncology (1997), Lippincott-Raven, Philadelphia (PA) 919-986
3. Shih I., and Kurman R.J. Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin Cancer Res 11 (2005) 7273-7279
4. Bast Jr. R.C., Badgwell D., Lu Z., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 Suppl 3 (2005) 274-281
5. Odegaard E., Davidson B., Elgaaen B.V., et al. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 198 (2008) 418.e1-418.e7
6. Fonsatti E., Altomonte M., Nicotra M.R., Natali P.G., and Maio M. Endoglin (CD105): A powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 22 (2003) 6557-6563
7. Duff S.E., Li C., Garland J.M., and Kumar S. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J 17 (2003) 984-992
8. Kumar S., Ghellal A., Li C., et al. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59 (1999) 856-861
9. Vermeulen P.B., Roland L., Mertens V., et al. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res 51 (1996) 164-174
10. Fonsatti E., and Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2 (2004) 18
11. Salvesen H.B., Gulluoglu M.G., Stefansson I., and Akslen L.A. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS 111 (2003) 1011-1018
12. Saad R.S., Jasnosz K.M., Tung M.Y., and Silverman J.F. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 22 (2003) 248-253
13. Erdem O., Taskiran C., Onan M.A., Erdem M., Guner H., and Ataoglu O. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol 103 (2006) 1007-1011
14. Taskiran C., Erdem O., Onan A., et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 16 (2006) 1789-1793
15. Wang J.M., Wilson P.B., Kumar S., Pye D., and Hunter R.D. Quantitation of endothelial cell specific protein E-9 employing a single monoclonal antibody in an indirect sandwich ELISA. J Immunol Methods 171 (1994) 55-64
16. Takahashi N., Kawanishi-Tabata R., Haba A., et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 7 (2001) 524-532
17. Li C., Guo B., Wilson P.B., et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89 (2000) 122-126
18. Beresford M.J., Harris A.L., Ah-See M., Daley F., Padhani A.R., and Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 95 (2006) 1683-1688
19. Staff A.C., Braekke K., Johnsen G.M., Karumanchi A., and Harsem N.K. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum as well as amniotic fluid in preeclampsia. Am J Obstet Gynecol (2007) 176.e1-176.e6
20. Canevari S., Gariboldi M., Reid J.F., Bongarzone I., and Pierotti M.A. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 60 (2006) 19-37
21. Pezzella F., Pastorino U., Tagliabue E., et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151 (1997) 1417-1423
22. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., and Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 60 (2000) 1388-1393
23. Henriksen R., Gobl A., Wilander E., Oberg K., Miyazono K., and Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73 (1995) 213-220
24. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649
25. Simak J., and Gelderman M.P. Cell membrane microparticles in blood and blood products: Potentially pathogenic agents and diagnostic markers. Transfus Med Rev 20 (2006) 1-26
26. Ocana A., Rodriguez-Barbero A., Pericacho M., et al. Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients. Cancer Lett 255 (2007) 71-76